Pharming Group Nv (PHAR) has released an update.
Pharming Group N.V. has announced the completion of patient enrollment for a Phase III clinical trial of leniolisib, aimed at treating children with a rare immunodeficiency known as APDS. The trial seeks to establish the safety and efficacy of the drug in children aged 4 to 11, with the goal of expanding the drug’s approval to younger patients. This milestone follows the FDA’s approval of leniolisib for older patients and reflects the company’s commitment to addressing unmet medical needs in pediatric care.
For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.
